Atara Biotherapeutics Stock Current Valuation
| ATRA Stock | USD 6.63 0.11 1.63% |
Valuation analysis of Atara Biotherapeutics helps investors to measure Atara Biotherapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of March 23, 2025, Enterprise Value Over EBITDA is expected to decline to -1.45. In addition to that, Enterprise Value Multiple is expected to decline to -1.45. Fundamental drivers impacting Atara Biotherapeutics' valuation include:
Overvalued
Today
Please note that Atara Biotherapeutics' price fluctuation is risky at this time. Calculation of the real value of Atara Biotherapeutics is based on 3 months time horizon. Increasing Atara Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Atara Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Atara Stock. However, Atara Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.63 | Real 6.36 | Target 16.5 | Hype 6.63 | Naive 9.26 |
The real value of Atara Stock, also known as its intrinsic value, is the underlying worth of Atara Biotherapeutics Company, which is reflected in its stock price. It is based on Atara Biotherapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Atara Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Atara Biotherapeutics helps investors to forecast how Atara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Atara Biotherapeutics more accurately as focusing exclusively on Atara Biotherapeutics' fundamentals will not take into account other important factors: Atara Biotherapeutics Company Current Valuation Analysis
Atara Biotherapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Atara Biotherapeutics Current Valuation | 40.77 M |
Most of Atara Biotherapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atara Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Atara Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Atara Biotherapeutics is extremely important. It helps to project a fair market value of Atara Stock properly, considering its historical fundamentals such as Current Valuation. Since Atara Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Atara Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Atara Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Atara Biotherapeutics has a Current Valuation of 40.77 M. This is 99.72% lower than that of the Biotechnology sector and 99.12% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.75% higher than that of the company.
Atara Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atara Biotherapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atara Biotherapeutics could also be used in its relative valuation, which is a method of valuing Atara Biotherapeutics by comparing valuation metrics of similar companies.Atara Biotherapeutics is currently under evaluation in current valuation category among its peers.
Atara Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Atara Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Atara Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Atara Fundamentals
| Return On Equity | -20.15 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (0.66) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 40.77 M | ||||
| Shares Outstanding | 5.86 M | ||||
| Shares Owned By Insiders | 21.90 % | ||||
| Shares Owned By Institutions | 50.50 % | ||||
| Number Of Shares Shorted | 674.63 K | ||||
| Price To Earning | (4.50) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 0.30 X | ||||
| Revenue | 128.94 M | ||||
| Gross Profit | (39.8 M) | ||||
| EBITDA | (75.75 M) | ||||
| Net Income | (85.4 M) | ||||
| Cash And Equivalents | 331.31 M | ||||
| Cash Per Share | 3.51 X | ||||
| Total Debt | 29.91 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 5.28 X | ||||
| Book Value Per Share | (16.60) X | ||||
| Cash Flow From Operations | (68.72 M) | ||||
| Short Ratio | 5.64 X | ||||
| Earnings Per Share | (11.41) X | ||||
| Target Price | 12.25 | ||||
| Number Of Employees | 153 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 38.84 M | ||||
| Total Asset | 109.1 M | ||||
| Retained Earnings | (2.05 B) | ||||
| Working Capital | (69.68 M) | ||||
| Current Asset | 324.6 M | ||||
| Current Liabilities | 9.71 M | ||||
| Net Asset | 109.1 M |
About Atara Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atara Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atara Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atara Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Atara Biotherapeutics Piotroski F Score and Atara Biotherapeutics Altman Z Score analysis. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.41) | Revenue Per Share | Quarterly Revenue Growth 6.703 | Return On Assets | Return On Equity |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.